Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies-Reference-Cited by-同舟云学术

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

Published:2022-01-11 Issue:6 Volume:63 Page:1375-1386
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Burger Jan A.¹,Robak Tadeusz²^ORCID,Demirkan Fatih³,Bairey Osnat⁴,Moreno Carol⁵,Simpson David⁶,Munir Talha⁷,Stevens Don A.⁸,Dai Sandra⁹,Cheung Leo W. K.⁹,Kwei Kevin⁹,Lal Indu⁹,Hsu Emily⁹,Kipps Thomas J.¹⁰,Tedeschi Alessandra¹¹

Affiliation:

1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland

3. Dokuz Eylul University, Izmir, Turkey

4. Rabin Medical Center, Petah Tikva, Israel

5. Hospital de la Santa Creu I Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

6. BeiGene, San Mateo, CA, USA

7. Department of Haematology, St. James’s Hospital, Leeds, United Kingdom

8. Norton Cancer Institute, Louisville, KY, USA

9. Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA

10. University of California San Diego, Moores Cancer Center, La Jolla, CA, USA

11. ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy